Table of Contents
Innocreate SARS-CoV-2 QD Kit Receives TFDA Manufacturing Approval
TFDA Manufacturing Approval serves as the definitive seal of quality and safety for medical devices in Taiwan, and Innocreate Bioscience is proud to announce that our advanced diagnostic solution has officially reached this milestone. On July 24, 2020, the Taiwan Food and Drug Administration (TFDA) granted manufacturing approval to the Innocreate SARS-CoV-2 QD Kit. This significant achievement marks a pivotal turning point in our company’s mission to provide high-precision tools for public health, especially during a time when global diagnostic capacity is under extreme pressure.
This TFDA Manufacturing Approval is not just a regulatory formality; it is a validation of the rigorous scientific standards and manufacturing excellence maintained at our facility in New Taipei City. We would like to extend our deepest gratitude to our partners, government consultants, and the scientific community for their unwavering support as we join the global effort to combat the pandemic through superior diagnostic technology.
Precision Engineering for Reliable Results
The Innocreate SARS-CoV-2 QD Kit was engineered to address the most common challenges in viral diagnostics: the high stakes of false-positive and false-negative results. In a pandemic scenario, a false negative can lead to community spread, while a false positive can cause unnecessary quarantine and strain on resources. To mitigate these risks, the kit features a sophisticated multiplex design that targets three essential viral markers: the E, N, and RdRP genes.
By targeting multiple regions of the viral genome, the kit ensures that the detection remains robust even as the virus undergoes mutations. If one region of the virus evolves slightly, the other two targets ensure the kit remains effective. This multi-target strategy was a core component of the data submitted to achieve our TFDA Manufacturing Approval.
Technical Excellence & Efficiency
Beyond its high accuracy, the Innocreate SARS-CoV-2 QD Kit stands out in the market due to its extreme sensitivity and streamlined workflow, which are critical for high-volume testing centers.
- Rapid Turnaround Time: Utilizing “Fast Mode” qPCR, laboratories can obtain definitive results in under 50 minutes. This speed is essential for hospital triage and airport screening protocols.
- Extreme Sensitivity: The kit reaches a Limit of Detection (LOD) of 2 PFU/ml. This allows for the detection of “silent” carriers—individuals with extremely low viral loads who might otherwise go undetected by less sensitive assays.
- Internal Integrity Control: A human gene target (RNase P) is included in every reaction. This serves as an internal control to verify that a proper sample was collected from the patient. This prevents “false negatives” that occur when a swab fails to pick up enough cellular material.
- Increased Throughput: Because the kit uses a multiplex design, all viral and control targets are detected in fewer reactions. This allows laboratories to process more patient samples per day without increasing their hardware footprint.
Quality Control and Scalability
Following the receipt of our TFDA Manufacturing Approval, Innocreate Bioscience has implemented a simplified operational protocol designed to minimize human error. In high-pressure testing environments, the complexity of a test can often lead to mistakes. Our kit is designed for consistent quality, ensuring that a test performed in a regional clinic is just as accurate as one performed in a major research hospital.
“Our goal was to create a tool that combines laboratory-grade precision with the efficiency required for mass screening,” says the technical team at Innocreate Bioscience. “With the TFDA Manufacturing Approval now in hand, we are ready to scale our manufacturing to meet the urgent needs of healthcare providers and public health agencies both locally and internationally.”
We look forward to working with international health organizations to bring this technology to the front lines where it is needed most. For detailed technical specifications or to discuss distribution opportunities, please visit the official Innocreate Bioscience website. Together, we can ensure that every patient has access to the fast and accurate diagnosis they deserve.
